Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ezetimibe/simvastatin

- PMLiVE

Merck and Sun Pharma part company on branded generics

Will continue partnership on diabetes and inflammatory disorder projects

- PMLiVE

Mylan agrees to buy Sweden’s Meda for $7.2bn

Deal is set to boost its over-the-counter medicines portfolio 

- PMLiVE

Opt in or opt out?

Changes to European patent law raise a number of questions for the industry

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

- PMLiVE

Germany’s Merck triumphs in court battle with US namesake

English court rules Merck & Co breached the firms' naming agreement

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

Roche Basel Switzerland

Roche prepares to file atezolizumab for bladder cancer

Imminent submission to the FDA after additional positive phase II trial results

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

- PMLiVE

MSD appoints Jessica Fine as UK external affairs director

She joins the UK pharma company from Lexington Health

- PMLiVE

Merck finally bags FDA approval for Bridion

Follows three unsuccessful attempts to gain a US licence for the drug

- PMLiVE

FDA panel rejects cardiovascular outcomes claim for Vytorin

Merck & Co fail to convince regulator's advisors

- PMLiVE

Another lost decade for research?

What does the patent landscape look like for antibiotics, vaccines and orphan drugs?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links